Company news, research breakthroughs, and major announcements across industries.

Home/Science

Science |AI Proteins

AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million

Logo-Gradient-Dark.jpg
Logo-Gradient-Dark.jpg

AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, today announced it has entered into a Research Collaboration and License Agreement with Astellas Innovation Management LLC, an affiliate of Astellas Pharma Inc. (TSE: 4503), to discover and develop novel miniprotein-based therapeutics. Under the terms of the agreement, AI Proteins is eligible to receive over $400 million in upfront and milest...

  • PublishedOctober 21, 2026 · 8:00 AM
  • LocationBOSTON
  • IndustryScience
  • LanguageEN

Published by Business Wire. Read the original announcement for the full release.

Read the full announcement →

Latest from leading organizations

Explore recent announcements by organization